Bloomberg-- Novartis AG is betting on a clutch of combination heart pills to replace revenue from its best-selling hypertension drug Diovan, after its most-promising cancer treatment was delayed by three months.
Bloomberg-- Novartis AG is betting on a clutch of combination heart pills to replace revenue from its best-selling hypertension drug Diovan, after its most-promising cancer treatment was delayed by three months.
